NEWS
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
Personalis announced at ASCO that their NeXT Personal test showed exceptional performance in early-stage breast cancer recurrence detection and immunotherapy monitoring. The test, an ultra-sensitive liquid biopsy, can detect circulating tumor DNA (ctDNA) down to less than 100 parts per million. Results indicated a ~15-month lead time over traditional imaging methods in detecting recurrence, with 100% accuracy in identifying recurrence and cancer-free states. Additionally, for HER2+ breast cancer, NeXT Personal demonstrated a 92% baseline sensitivity for ctDNA. For immunotherapy monitoring, significant decreases in ctDNA levels corresponded to more than double the overall survival rates. These findings suggest strong potential for NeXT Personal in clini
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1114Followers
70Following
7775Visitors
Follow